

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

**Avatrombopag in combination for treating chronic immune thrombocytopenia
ID3838**

Final Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Swedish Orphan Biovitrum (avatrombopag) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Genetic Alliance UK • ITP Support Association • Lymphoma Action • South Asian Health Foundation • Specialised Healthcare Alliance • TTP Network • AOFAC Foundation <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Society for Haematology • British Society for Genetic Medicine • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Genetic Testing Network • UK ITP Forum • United Kingdom Cutaneous Lymphoma Group • Immunodeficiency UK <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bromley CCG • NHS England • NHS North Lincolnshire CGG • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (mycophenolate mofetil) • Accord UK (dapsone, mycophenolate mofetil) • Amgen (romiplostim) • Aspen (azathioprine) • Dexcel Pharma (ciclosporin) • Ennogen (azathioprine) • Grifols (fostamatinib) • Mylan (azathioprine, ciclosporin) • Napp Pharmaceuticals (rituximab) • Novartis Pharmaceuticals (ciclosporin, eltrombopag) • Pfizer (rituximab) • Roche (rituximab, mycophenolate mofetil) • Rivopharm (dapsone) • Sandoz (rituximab)

Final stakeholder list for the health technology appraisal of avatrombopag in combination for treating chronic immune thrombocytopenia ID3838. Issue date: July 2021

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Sanofi (danazol) • Teva Pharma BV (mycophenolate mofetil) • Tillomed Laboratories (azathioprine, dapsons, mycophenolate mofetil) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Cochrane Haematological Malignancies Group • Lymphoma UK <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC],

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.